Reduced susceptibility to carbapenems in Klebsiella pneumoniae clinical isolates associated with plasmid-mediated β-lactamase production and OmpK36 porin deficiency
Two carbapenem-non-susceptible Klebsiella pneumoniae isolates, Z2554 and Z2110, were collected from a hospital in China and analysed by PFGE. K. pneumoniae Z2554 and Z2110 were genetically unrelated and showed resistance to ertapenem, and reduced susceptibility to imipenem and meropenem. Analysis of their β-lactamases indicated that K. pneumoniae Z2554 produced TEM-1 and CTX-M-14 β-lactamases, whilst Z2110 produced a plasmid-mediated AmpC β-lactamase, DHA-1, in addition to TEM-1 and CTX-M-14. SDS-PAGE analysis of the outer-membrane proteins (OMPs) revealed that both isolates lacked an OMP of ∼39 kDa (OmpK36), whilst Z2110 had an additional protein with an approximate molecular mass of 26 kDa. Analysis of the OMP-encoding genes demonstrated that the ompK35 sequence of K. pneumoniae Z2554 and Z2110 contained a number of silent mutations. In ompK36, several insertions and deletions of short DNA fragments (1–6 bp) were detected in both isolates. The N-terminal sequence of the ∼26 kDa protein band identified in Z2110 had no similarity to the sequence of OmpK36. Instead, it shared high similarity with hypothetical protein KPN_03267 originating from K. pneumoniae subsp. pneumoniae MGH 78578. It was concluded that β-lactamase production combined with OmpK36 deficiency results in ertapenem resistance, and reduced imipenem and meropenem susceptibility, in K. pneumoniae Z2554 and Z2110. OmpK36 may play an important role in the resistance or reduced susceptibility to carbapenems in K. pneumoniae producing AmpC, extended-spectrum β-lactamase or broad-spectrum β-lactamase.
BradfordP. A.,
UrbanC.,
MarianoN.,
ProjanS. L.,
RahalJ. J.,
BushK.1997; Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC β -lactamase, and the loss of an outer membrane protein. Antimicrob Agents Chemother 41:563–569
CaiJ. C.,
ZhouH. W.,
ZhangR.,
ChenG. X.2008; Emergence of Serratia marcescens , Klebsiella pneumoniae and Escherichia coli possessing the plasmid-mediated carbapenem-hydrolyzing β -lactamase KPC-2 in intensive care units of a Chinese hospital. Antimicrob Agents Chemother 52:2014–2018[CrossRef]
CaoV. T.,
ArletG.,
EricssonB. M.,
TammelinA.,
CourvalinP.,
LambertT.2000; Emergence of imipenem resistance in Klebsiella pneumoniae owing to combination of plasmid-mediated CMY-4 and permeability alteration. J Antimicrob Chemother 46:895–900[CrossRef]
CLSI2006Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically , approved standard M7–A7 Wayne, PA: Clinical and Laboratory Standards Institute;
CrowleyB.,
BenedíV. J.,
Doménech-SánchezA.2002; Expression of SHV-2 β -lactamase and of reduced amounts of OmpK36 porin in Klebsiella pneumoniae results in increased resistance to cephalosporins and carbapenems. Antimicrob Agents Chemother 46:3679–3682[CrossRef]
Doménech-SánchezA.,
Hernández-AllésS.,
Martínez-MartínezL.,
BenedíV. J.,
AlbertíS.1999; Identification and characterization of a new porin gene of Klebsiella pneumoniae : its role in β -lactam antibiotic resistance. J Bacteriol 181:2726–2732
Doménech-SánchezA.,
Martínez-MartínezL.,
Hernández-AllésS.,
ConejoM. C.,
PascualA.,
TomásJ. M.,
AlbertíS.,
BenedíV. J.2003; Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother 47:3332–3335[CrossRef]
ElliottE.,
BrinkA. J.,
van GreuneJ.,
ElsZ.,
WoodfordN.,
TurtonJ.,
WarnerM.,
LivermoreD. M.2006; In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum β -lactamase. Clin Infect Dis 42:e95–e98[CrossRef]
JacobyG. A.,
MillsD. M.,
ChowN.2004; Role of β -lactamases and porins in resistance to ertapenem and other β -lactams in Klebsiella pneumoniae
. Antimicrob Agents Chemother 48:3203–3206[CrossRef]
KaczmarekF. M.,
Dib-HajjF.,
ShangW.,
GootzT. D.2006; High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla ACT-1β -lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin PhoE. Antimicrob Agents Chemother 50:3396–3406[CrossRef]
LeeC. H.,
ChuC.,
LiuJ. W.,
ChenY. S.,
ChiuC. J.,
SuL. H.2007a; Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of bla DHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 β -lactamases. J Antimicrob Chemother 60:410–413[CrossRef]
LeeK.,
YongD.,
ChoiY. S.,
YumJ. H.,
KimJ. K.,
WoodfordN.,
LivermoreD. M.,
ChongY.2007b; Reduced imipenem susceptibility in Klebsiella pneumoniae clinical isolates with plasmid-mediated CMY-2 and DHA-1 β -lactamases co-mediated by porin loss. Int J Antimicrob Agents 29:201–206[CrossRef]
LincopanN.,
McCullochJ. A.,
ReinertC.,
CassettariV. C.,
GalesA. C.,
MamizukaE. M.2005; First isolation of metallo- β -lactamase-producing multiresistant Klebsiella pneumoniae from a patient in Brazil. J Clin Microbiol 43:516–519[CrossRef]
Martínez-MartínezL.,
Hernández-AllésS.,
AlbertíS.,
TomásJ. M.,
BenedíV. J.,
JacobyG. A.1996; In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum cephalosporins. Antimicrob Agents Chemother 40:342–348
MathewA.,
HarrisA. M.,
MarshallM. J.,
RossG. W.1975; The use of analytical isoelectric focusing for detection and identification of β -lactamase. J Gen Microbiol 88:169–178[CrossRef]
MenaA.,
PlasenciaV.,
GarcíaL.,
HidalgoO.,
AyestaránJ. I.,
AlbertiS.,
BorrellN.,
PérezJ. L.,
OliverA.2006; Characterization of a large outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development. J Clin Microbiol 44:2831–2837[CrossRef]
RiceL. B.,
CariasL. L.,
EtterL.,
ShlaseD. M.1993; Resistance to cefoperazone-sulbactam in Klebsiella pneumoniae : evidence for enhanced resistance resulting from the coexistence of two different resistance mechanisms. Antimicrob Agents Chemother 37:1061–1064[CrossRef]
TenoverF. C.,
ArbeitR. D.,
GoeringR. V.,
MickelsenP. A.,
MurrayB. E.,
PersingD. H.,
SwaminathanB.1995; Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33:2233–2239
WoodfordN.,
TiernoP. M.,
YoungK.Jr,
TysallL.,
PalepouM.-F. I.,
WardE.,
PainterR. E.,
SuberD. F.,
ShunguD.other authors2004; Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β -lactamase, KPC-3, in a New York medical center. Antimicrob Agents Chemother 48:4793–4799[CrossRef]
YanJ. J.,
KoW. C.,
TsaiS. H.,
WuH. M.,
WuJ. J.2001; Outbreak of infection with multidrug-resistant Klebsiella pneumoniae carrying bla IMP-8 in a university medical center in Taiwan. J Clin Microbiol 39:4433–4439[CrossRef]
ZhangR.,
YangL.,
CaiJ. C.,
ZhouH. W.,
ChenG. X.2008; High-level carbapenem resistance in a Citrobacter freundii clinical isolate is due to a combination of KPC-2 production and decreased porin expression. J Med Microbiol 57:332–337[CrossRef]
Reduced susceptibility to carbapenems in Klebsiella pneumoniae clinical isolates associated with plasmid-mediated β-lactamase production and OmpK36 porin deficiency